Cargando…

Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome

BACKGROUND: Although the clinical benefit of imatinib adjuvant therapy for high-risk patients with gastrointestinal stromal tumor (GIST) has been proven, the recurrence rate still remains high. This study aimed to sub-divide high-risk GIST patients with some “very high-risk” factors for more precise...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Wen-Yi, Xu, Jia, Wang, Ming, Zhang, Zi-Zhen, Tu, Lin, Wang, Chao-Jie, Cao, Hui, Zhang, Zhi-Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057930/
https://www.ncbi.nlm.nih.gov/pubmed/24906683
http://dx.doi.org/10.1186/1471-230X-14-105
_version_ 1782321047339532288
author Zhao, Wen-Yi
Xu, Jia
Wang, Ming
Zhang, Zi-Zhen
Tu, Lin
Wang, Chao-Jie
Cao, Hui
Zhang, Zhi-Gang
author_facet Zhao, Wen-Yi
Xu, Jia
Wang, Ming
Zhang, Zi-Zhen
Tu, Lin
Wang, Chao-Jie
Cao, Hui
Zhang, Zhi-Gang
author_sort Zhao, Wen-Yi
collection PubMed
description BACKGROUND: Although the clinical benefit of imatinib adjuvant therapy for high-risk patients with gastrointestinal stromal tumor (GIST) has been proven, the recurrence rate still remains high. This study aimed to sub-divide high-risk GIST patients with some “very high-risk” factors for more precise prognostic indicator, and possible association with efficiency of imatinib adjuvant therapy. METHODS: Clinicopathological data were confirmed by pathological diagnosis and clinical records. Recurrence-free survivals (RFS) were evaluated in 370 GIST patients (212 cases as test cohort and 158 cases as validation cohort) and 48 high-risk GISTs with imatinib adjuvant therapy after R0 resection. RESULTS: Mitosis count > 10/50 high-power fields (HPF) and serosal invasion are independent prognostic factors for RFS of GIST patients. Mitosis count > 10/50HPF and serosal invasion can sub-divide high-risk GIST patients effectively and significantly improve the area under the curve (AUC) of receiver operating characteristics (ROC) curve for prognostic indicator both in test and validation cohort. Patients with serosal invasion after R0 resection showed a poorer prognosis with imatinib adjuvant therapy. CONCLUSIONS: Sub-division of high-risk GIST patients helps to more precisely predicting the prognosis. Serosal invasion may be an adverse predictive factor in high-risk patients and imatinib treatment outcome.
format Online
Article
Text
id pubmed-4057930
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40579302014-06-15 Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome Zhao, Wen-Yi Xu, Jia Wang, Ming Zhang, Zi-Zhen Tu, Lin Wang, Chao-Jie Cao, Hui Zhang, Zhi-Gang BMC Gastroenterol Research Article BACKGROUND: Although the clinical benefit of imatinib adjuvant therapy for high-risk patients with gastrointestinal stromal tumor (GIST) has been proven, the recurrence rate still remains high. This study aimed to sub-divide high-risk GIST patients with some “very high-risk” factors for more precise prognostic indicator, and possible association with efficiency of imatinib adjuvant therapy. METHODS: Clinicopathological data were confirmed by pathological diagnosis and clinical records. Recurrence-free survivals (RFS) were evaluated in 370 GIST patients (212 cases as test cohort and 158 cases as validation cohort) and 48 high-risk GISTs with imatinib adjuvant therapy after R0 resection. RESULTS: Mitosis count > 10/50 high-power fields (HPF) and serosal invasion are independent prognostic factors for RFS of GIST patients. Mitosis count > 10/50HPF and serosal invasion can sub-divide high-risk GIST patients effectively and significantly improve the area under the curve (AUC) of receiver operating characteristics (ROC) curve for prognostic indicator both in test and validation cohort. Patients with serosal invasion after R0 resection showed a poorer prognosis with imatinib adjuvant therapy. CONCLUSIONS: Sub-division of high-risk GIST patients helps to more precisely predicting the prognosis. Serosal invasion may be an adverse predictive factor in high-risk patients and imatinib treatment outcome. BioMed Central 2014-06-07 /pmc/articles/PMC4057930/ /pubmed/24906683 http://dx.doi.org/10.1186/1471-230X-14-105 Text en Copyright © 2014 Zhao et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Zhao, Wen-Yi
Xu, Jia
Wang, Ming
Zhang, Zi-Zhen
Tu, Lin
Wang, Chao-Jie
Cao, Hui
Zhang, Zhi-Gang
Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome
title Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome
title_full Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome
title_fullStr Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome
title_full_unstemmed Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome
title_short Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome
title_sort evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057930/
https://www.ncbi.nlm.nih.gov/pubmed/24906683
http://dx.doi.org/10.1186/1471-230X-14-105
work_keys_str_mv AT zhaowenyi evaluationofhighriskclinicopathologicalindicatorsingastrointestinalstromaltumorsforprognosisandimatinibtreatmentoutcome
AT xujia evaluationofhighriskclinicopathologicalindicatorsingastrointestinalstromaltumorsforprognosisandimatinibtreatmentoutcome
AT wangming evaluationofhighriskclinicopathologicalindicatorsingastrointestinalstromaltumorsforprognosisandimatinibtreatmentoutcome
AT zhangzizhen evaluationofhighriskclinicopathologicalindicatorsingastrointestinalstromaltumorsforprognosisandimatinibtreatmentoutcome
AT tulin evaluationofhighriskclinicopathologicalindicatorsingastrointestinalstromaltumorsforprognosisandimatinibtreatmentoutcome
AT wangchaojie evaluationofhighriskclinicopathologicalindicatorsingastrointestinalstromaltumorsforprognosisandimatinibtreatmentoutcome
AT caohui evaluationofhighriskclinicopathologicalindicatorsingastrointestinalstromaltumorsforprognosisandimatinibtreatmentoutcome
AT zhangzhigang evaluationofhighriskclinicopathologicalindicatorsingastrointestinalstromaltumorsforprognosisandimatinibtreatmentoutcome